KRAS and cancer: Establishment of Drosophila as a personalized cancer drug discovery platform, targeting KRAS-mutant metastatic colorectal cancer. Subsequent drug screening using this model revealed the potential effect of trametinib and zoledronate for metastatic colorectal cancer